SUMMARY The hydrolysis of radiolabelled Escherichia coli phospholipids, and micellar dispersions of phosphatidylethanolamine and phosphatidylcholine, were used to characterise the phospholipase A2 activity in synovial fluid from patients with rheumatoid arthritis. Cell free fractions of synovial fluid contain a phospholipase A2 enzyme that preferentially releases [14CJoleic acid from E coli biomembranes (specific activity Prostaglandins and hydroxyl compounds of arachidonic acid are potent mediators of the inflammatory response identified in inflammatory sites in patients with rheumatoid arthritis. For example, prostaglandin E2 and leucotriene B4 have been found in the synovial fluid' 2; while 5-hydroxyeicosatetraenoic acid has been identified in synovial tissues.3 Prostaglandin E2 as a vasodilator and hyperalgesic agent may cause erythema, oedema, and pain.4 Leucotriene B4 provokes a variety of responses in neutrophils, including chemotaxis, mobilisation of calcium, aggregation, release of lysosomal enzymes, and generation of superoxide anions.5 5-Hydroxyeicosatetraenoic acid is also chemotactic for neutro-
phils. It is possible that these agents act sequentially and in combination to produce local oedema and cellular migration into the rheumatic joint. The release of arachidonic acid from membrane phospholipids, presumably by phospholipase A2, is believed to be the rate limiting step for the generation of this family of biologically active metabolites of arachidonic acid. Recently, high concentrations of phospholipase A2 have been detected in synovial fluid,6 peripheral blood neutrophils,8 and peripheral blood mononuclear cells9 from patients with rheumatoid arthritis. Although no correlation has been found between the concentrations of phospholipase A2 in rheumatoid synovial fluid and the clinical activity of the disease, it has been suggested that proinflammatory phospholipase A2 may have a contributory role in the pathogenesis of rheumatoid arthritis.69 This paper reports the biochemical properties of a soluble phospholipase A2 present in cell free fractions of synovial fluid from patients with rheumatoid arthritis. We determined the substrate specificity of this enzyme based on the hydrolysis of phospholipids from radiolabelled E coli biomembranes, and purified micellar dispersions of radiolabelled phosphatidylethanolamine and phosphatidylcholine. The possibility of two different enzymes with phospholipase A2 activity in the rheumatoid synovial fluid is suggested.
Materials and methods

SYNOVIAL FLUIDS AND PERIPHERAL BLOOD CELLS
Synovial fluid from 11 patients with classical or definite rheumatoid arthritis as defined by the American Rheumatism Association criterial were investigated. All patients were taking a nonsteroidal anti-inflammatory drug, two patients were also receiving 2*5 mg of prednisone daily. Synovial fluid was obtained from the knee joint during a flare up of the disease. Peripheral blood cells from three patients were obtained at the same time as the synovial fluid aspiration. Cells were removed from the synovial fluid by immediate centrifugation at 4°C, 900 rpm (280 g) for 10 minutes. Polymorphonuclear neutrophils were separated from mononuclear cells by Lymphoprep (Gallard-Schlesinger, NY) gradient centrifugation at 1400 rpm (380 g) for 30 minutes at room temperature as previously described.'1 12 Contaminating erythrocytes were removed by a brief hypotonic lysis, and the cells were resuspended in Dulbecco's phosphate buffered saline pH 7.4 (Gifco, Grand Island, NY). Cell suspensions were sonicated for 30 seconds (setting 4) using a Branson ultrasonic probe. The cell free fraction of synovial fluid was diluted with 0-9% saline to bring the protein to within the linear range of the assay. Peripheral blood neutrophils and peripheral blood mononuclear cells were isolated from whole heparinised blood (10 units of either the ionic detergent deoxycholic acid or the non-ionic detergent Triton X-100 to the reaction mixture did not affect phospholipase A2 activity. Several variables of phospholipid hydrolysis by cell free synovial fluid phospholipase A2 were examined using labelled E coli substrate. Our studies suggest that synovial fluid neutrophils fluid phospholipase A2 activity in assay and mononuclear cells may be important sources of containing bovine serum albumin6 7 the phospholipase A2. Synovial fluid neutrophils exalbumin was determined using both sub-press up to 10 times more activity than those from The presence of bovine serum albumin in peripheral blood ( 23 all reported in the rheumatoid the first report on phospholipid substrate synovial fluid, may act as activators of cellular ty for a phospholipase A2 present in the phospholipase A2. This would then trigger mobilisafluid from patients with rheumatoid arthrit-tion of free arachidonic acid and further metabol--stablished standard assay conditions and ism, leading to raised concentrations of inflammarised the phospholipase A2 activity in cell tory eicosanoids in the synovial fluid. Chang et al ovial fluid from rheumatoid patients. In have recently proposed that the inflammatory , publications6 7 phospholipase A2 activity actions of interleukin 1 may be mediated through expressed in units/ml, which does not allow activation of a phospholipase A2, leading to generacomparison because of the variability in tion of biologically active metabolites of arachidonic fluid protein concentrations. We suggest, acid.24 In support of this interesting hypothesis they e, the measurement of specific activity in showed that interleukin 1 induces intracellular substrate hydrolysed per minute per mg of phospholipase A2 activity in rabbit articular chonas the appropriate units for expression of drocytes and stimulates secretion of phospholipase ic activity. Cell free synovial fluid phospho-A2 into the culture medium. Furthermore, they L2 hydrolysed phospholipids from E coli showed a dose related synthesis of prostaglandin E2 branes, and purified micellar dispersions of by these interleukin 1 The cell free synovial fluid phospholipase A2 described here, which readily hydrolyses E coli phospholipids, is similar to the enzyme characterised by Vadas et al. 7 Although the results show that Ecolicardiolipin and phosphatidylethanolamine/ phosphatidylglycerol as presented in these experiments are accepted as substrate by the cell associated phospholipase A2, further studies are clearly needed to establish its substrate specificity and its relation with the phospholipase A2 in neutrophils and mononuclear cells from patients with rheumatoid arthritis, as described by Bomalaski etal. 8 9 Although the relevance of these phospholipase A2s to the chronic inflammatory process in rheumatoid arthritis is presently unknown, lysoderivatives of phosphatidylserine, phosphatidylcholine, and phosphatidylethanolamine have been reported in rheumatoid synovial fluid, suggesting the possibility of active phospholipid hydrolysis occurring in the joint space.
The above observations taken together with the other reports cited confirm the presence of proinflammatory phospholipase A2 in rheumatoid synovial fluid. Furthermore, cell free fractions of synovial fluid contain an apparently different phospholipase A2 than the cell associated form present in synovial fluid neutrophils and mononuclear cells. The results of this study may help to explain the abnormal regulation of eicosanoid production observed in rheumatoid arthritis. 
